Alex Therapeutics presents results from digital therapeutic pilot study showing nearly 50% reduction in anxiety
· The Digital Therapeutic (DTx) was developed by DTx leader Alex Therapeutics using the proprietary “Alex DTx Platform”[1] in partnership with Vicore Pharma · In the study patients with Idiopathic Pulmonary Fibrosis (IPF) and anxiety were given the DTx · Safety, functionality, and user experience were all studied and found positive · Average reduction in anxiety, GAD-7*, was 4.2 points · Pivotal phase of study is to be launched in Q4, 2022 Stockholm, 13th October, 2022 - Alex Therapeutics is a DTx Software-as-a-medical-device (SaMD) manufacturer developing and licensing